O	0	6	Effect
O	7	9	of
O	10	22	preoperative
O	23	28	short
O	29	35	course
B-intervention	36	46	famotidine
O	47	49	on
O	50	54	TILs
O	55	58	and
O	59	67	survival
O	68	70	in
O	71	77	breast
O	78	84	cancer
O	84	85	.

O	86	95	Histamine
O	96	104	receptor
O	105	116	antagonists
O	117	121	have
O	122	126	been
O	127	132	shown
O	133	135	to
O	136	142	induce
O	143	148	tumor
O	148	149	-
O	149	161	infiltrating
O	162	173	lymphocytes
O	174	175	(
O	175	179	TILs
O	179	180	)
O	181	183	in
O	184	191	colonic
O	192	199	cancers
O	200	203	and
O	204	211	improve
O	212	220	survival
O	220	221	.

O	222	225	The
O	226	230	role
O	231	233	of
O	234	243	histamine
O	244	252	receptor
O	253	265	anatagonists
O	266	268	in
O	269	275	breast
O	276	282	cancer
O	283	285	is
O	286	297	unclarified
O	297	298	.

O	299	301	To
O	302	310	evaluate
O	311	314	the
O	315	319	role
O	320	322	of
O	323	332	histamine
O	333	341	receptor
O	342	353	antagonists
O	354	356	in
O	357	365	inducing
O	366	367	(
O	367	371	TILs
O	371	372	)
O	373	375	in
O	376	382	breast
O	383	389	cancer
O	389	390	.

B-total-participants	391	396	Forty
I-total-participants	396	397	-
I-total-participants	397	401	five
B-eligibility	402	410	patients
I-eligibility	411	415	with
I-eligibility	416	424	operable
I-eligibility	425	431	breast
I-eligibility	432	439	cancers
O	440	441	(
B-intervention-participants	441	443	25
O	444	449	cases
O	450	453	who
O	454	462	received
O	463	475	preoperative
O	476	486	famotidine
O	487	490	and
B-control-participants	491	493	20
B-control	494	502	controls
O	502	503	)
O	504	508	were
O	509	516	studied
O	517	520	for
O	521	524	the
O	525	531	effect
O	532	534	of
O	535	545	famotidine
O	546	548	in
O	549	557	inducing
O	558	562	TILs
O	563	566	and
O	567	575	survival
O	576	578	in
O	579	585	breast
O	586	592	cancer
O	592	593	.

B-outcome	594	605	Significant
I-outcome	606	610	TILs
O	611	615	were
O	616	620	seen
O	621	623	in
B-iv-bin-percent	624	626	75
I-iv-bin-percent	626	627	%
O	628	629	(
B-iv-bin-abs	629	631	18
O	631	632	/
B-intervention-participants	632	634	24
O	634	635	)
O	636	638	of
O	639	644	cases
O	645	647	as
O	648	655	opposed
O	656	658	to
B-cv-bin-percent	659	661	35
I-cv-bin-percent	661	662	%
O	663	664	(
B-cv-bin-abs	664	665	7
O	665	666	/
B-control-participants	666	668	20
O	668	669	)
O	670	678	controls
O	678	679	.

O	680	682	In
O	683	691	logistic
O	692	702	regression
O	703	711	analysis
O	712	715	the
O	716	720	only
O	721	729	variable
O	730	735	found
O	736	738	to
O	739	741	be
O	742	752	predictive
O	753	755	of
O	756	760	TILs
O	761	764	was
O	765	775	famotidine
O	775	776	,
O	777	781	odds
O	782	787	ratio
O	788	789	7
O	789	790	.
O	790	793	324
O	794	795	(
O	795	796	1
O	796	797	.
O	797	800	693
O	800	801	-
O	801	803	31
O	803	804	.
O	804	807	686
O	807	808	)
O	809	810	P
O	810	811	=
O	811	812	0
O	812	813	.
O	813	816	008
O	816	817	.

O	818	820	In
O	821	824	Cox
O	824	825	'
O	825	826	s
O	827	837	regression
O	838	846	presence
O	847	849	of
O	850	854	TILs
O	855	858	was
O	859	868	favorably
O	869	879	associated
O	880	884	with
O	885	893	improved
O	894	901	disease
O	902	906	free
O	907	915	survival
O	916	918	at
O	919	920	a
O	921	927	median
O	928	934	follow
O	935	937	up
O	938	940	of
O	941	943	35
O	943	944	.
O	944	946	56
O	947	953	months
O	953	954	.

O	955	958	The
O	959	965	hazard
O	966	971	ratio
O	972	975	for
B-outcome	976	983	disease
I-outcome	984	991	relapse
O	992	995	was
O	996	997	3
O	997	998	.
O	998	1001	327
O	1002	1003	(
O	1003	1004	1
O	1004	1005	.
O	1005	1008	174
O	1008	1009	-
O	1009	1010	9
O	1010	1011	.
O	1011	1014	426
O	1014	1015	)
O	1016	1017	P
O	1017	1018	=
O	1018	1019	0
O	1019	1020	.
O	1020	1023	024
O	1024	1026	in
O	1027	1030	TIL
O	1031	1039	negative
O	1040	1042	as
O	1043	1051	compared
O	1052	1054	to
O	1055	1058	TIL
O	1059	1067	positive
O	1068	1076	patients
O	1076	1077	.

O	1078	1088	Famotidine
O	1089	1092	use
O	1093	1098	alone
O	1099	1102	was
O	1103	1106	not
O	1107	1118	significant
O	1119	1121	in
O	1122	1125	the
O	1126	1134	original
O	1135	1140	model
O	1140	1141	,
O	1142	1149	however
O	1149	1150	,
O	1151	1153	on
O	1154	1167	incorporation
O	1168	1170	of
O	1171	1179	quadrant
O	1180	1182	of
O	1183	1194	involvement
O	1195	1197	in
O	1198	1206	addition
O	1207	1209	to
O	1210	1215	other
O	1216	1227	established
O	1228	1238	prognostic
O	1239	1246	factors
O	1247	1249	in
O	1250	1253	the
O	1254	1259	above
O	1260	1272	multivariate
O	1273	1278	model
O	1278	1279	,
O	1280	1282	it
O	1283	1290	assumed
O	1291	1301	borderline
O	1302	1314	significance
O	1315	1319	with
O	1320	1321	a
O	1322	1328	hazard
O	1329	1334	ratio
O	1335	1338	for
B-outcome	1339	1346	disease
I-outcome	1347	1351	free
I-outcome	1352	1360	survival
O	1361	1362	3
O	1362	1363	.
O	1363	1366	404
O	1367	1368	(
O	1368	1369	1
O	1369	1370	.
O	1370	1373	005
O	1373	1374	-
O	1374	1376	11
O	1376	1377	.
O	1377	1380	531
O	1380	1381	,
O	1382	1383	P
O	1383	1384	=
O	1384	1385	0
O	1385	1386	.
O	1386	1389	049
O	1389	1390	)
O	1390	1391	.

O	1392	1404	Preoperative
O	1405	1410	short
O	1411	1417	course
O	1418	1428	famotidine
O	1429	1436	induces
O	1437	1441	TILs
O	1442	1444	in
O	1445	1451	breast
O	1452	1458	cancer
O	1458	1459	.

O	1460	1468	Patients
O	1469	1473	with
O	1474	1478	TILs
O	1479	1491	demonstrable
O	1492	1494	in
O	1495	1500	tumor
O	1501	1510	specimens
O	1511	1514	had
O	1515	1517	an
O	1518	1526	improved
B-outcome	1527	1534	disease
I-outcome	1535	1539	free
I-outcome	1540	1548	survival
O	1548	1549	.

O	1550	1560	Famotidine
O	1561	1564	may
O	1565	1572	improve
O	1573	1580	disease
O	1581	1585	free
O	1586	1594	survival
O	1595	1597	in
O	1598	1604	breast
O	1605	1611	cancer
O	1612	1615	and
O	1616	1621	these
O	1622	1630	findings
O	1631	1635	need
O	1636	1646	validation
O	1647	1649	in
O	1650	1656	larger
O	1657	1667	population
O	1668	1675	subsets
O	1675	1676	.
